Mounjaro vs. Ozempic: The Real Verdict, Price and All

Is Mounjaro better than Ozempic for weight loss?

On average, yes. The SURMOUNT-5 trial, published in May 2025, tested the two drugs head to head. It followed 751 adults with obesity. None of them had diabetes. Each person took the highest dose they could tolerate for 72 weeks.

People on tirzepatide, the drug in Mounjaro, lost about 20% of their body weight. People on semaglutide, the drug in Ozempic, lost about 14%. Waist size also fell more on tirzepatide. More people on tirzepatide reached every weight-loss goal the trial tracked, from 10% up to 25%.

One detail matters for the brand names. In the trial, semaglutide went up to 2.4 mg, the Wegovy dose. Ozempic stops at 2 mg. Tirzepatide went up to 15 mg, the same top dose as Mounjaro.

Semaglutide now has a higher dose too. In March 2026, the FDA approved a 7.2 mg dose, sold as Wegovy HD. In its own trial, called STEP UP, people on that dose lost about 19% of their weight. That was a separate trial, not a head-to-head test. An Ozempic prescription does not give you that dose.

These are averages, not a promise for one person. Your result depends on your dose, how long you stay on it, and your body.

Mounjaro vs Ozempic cost: which one is cheaper?

Paying cash, Ozempic usually costs less over a year. At its top dose of 2 mg, though, the Ozempic pen costs the same as Mounjaro. With insurance that covers either drug, both can cost as little as $25 a month. The table above shows each option. Here is what sits behind each price.

Mounjaro vs Ozempic brand pricing, no insurance

Lilly sells Mounjaro through LillyDirect, its own online pharmacy. It costs about $500 a month at every dose.

Novo Nordisk sells Ozempic through NovoCare, its own pharmacy program. With its savings offer, you can also get the same self-pay price at many retail pharmacies. Here is what Ozempic costs:

• Ozempic pen up to 1 mg: about $350 a month.
• Ozempic pen at 2 mg: about $500 a month, the same as Mounjaro.
• New Ozempic patients: about $200 for each of the first two fills, through Dec 31, 2026.
• Ozempic pill: about $150 a month at the lowest dose, and about $300 at the top dose.

Counting 13 four-week fills, a year of self-pay Mounjaro comes to about $6,500. A year of the Ozempic pen, with the two starter fills and staying at or below 1 mg, comes to about $4,200. NovoCare says it will update its prices after Dec 31, 2026.

Without any program, Mounjaro's list price is about $1,100 a month. That is Lilly's price for a 28-day box of four pens. A GoodRx coupon barely lowers it, so LillyDirect is the better cash route. Our Mounjaro without insurance and Ozempic without insurance guides go through every cash option.

Compounded tirzepatide vs compounded semaglutide

Compounded drugs are made by a pharmacy from the same active ingredient. They are not FDA-approved, and they are not Mounjaro or Ozempic. They usually cost less than the brand-name pens on this page.

Curex sells compounded tirzepatide with no membership fee. Its price covers the online visit, the medicine and shipping. On a year paid upfront, it costs from about $200 a month. Month to month, it costs about $250 for a tablet and about $300 for a shot, at the starting dose. Higher doses cost about $100 more.

Fridays sells compounded semaglutide for about $150 a month if you pay for a year upfront. Month to month, it costs about $280. Visits, a dietitian and coaching are included. Fridays does not refund a prepaid year if you stop early.

Month to month, Curex's tirzepatide tablet starts a little below Fridays' semaglutide. On a prepaid year, Fridays costs less.

With insurance and the manufacturer savings card

Here the two drugs cost about the same. Your commercial plan must cover the drug for type 2 diabetes. Commercial means private insurance, such as a plan through work. Then both savings cards can bring your cost down to as little as $25 a month.

Each card has a monthly limit. The Mounjaro card takes off up to $150 a month. The Ozempic card takes off up to $100. A deductible is the amount you pay each year before your plan starts to pay. With a high deductible, you may pay more than $25 until you reach it.

If your plan does not cover the drug, the cards still help. The Mounjaro card then brings the price to about $500, the same as LillyDirect. The Ozempic offer gives you NovoCare's self-pay price at a retail pharmacy.

Medicare, Medicaid and other government plans cannot use either card. The Mounjaro card ends on Dec 31, 2026. The details are in our Mounjaro savings card and Ozempic savings guides.

Are Mounjaro and Ozempic approved for weight loss?

No. Both are approved only for adults with type 2 diabetes. The FDA approved Ozempic in 2017. Mounjaro followed in May 2022.

The weight-loss approvals belong to their sister brands. Wegovy is semaglutide for weight loss. Zepbound is tirzepatide for weight loss.

A prescriber can still use Mounjaro or Ozempic for weight loss. This is called off-label use, meaning a use the FDA label does not list. It is legal and fairly common.

The label matters most for cost. Insurance pays by diagnosis, not by drug. A plan may cover Mounjaro for diabetes and deny the same drug for weight loss alone. The $25 savings cards also need a prescription that matches the diabetes label.

If weight loss is your main goal, ask about Zepbound or Wegovy instead. They contain the same drugs, and their coverage and savings programs are built for weight loss. See Zepbound cost and Wegovy cost. Ozempic vs. Wegovy explains how the two semaglutide brands differ.

Does insurance cover Mounjaro or Ozempic?

With type 2 diabetes, coverage for either drug is common but rarely automatic. Most plans want prior authorization first. That is a form your prescriber sends to show you meet the plan's rules.

The plan may ask for your A1C, a blood test of your average blood sugar. Some plans also want you to try a cheaper diabetes drug, such as metformin, first.

For weight loss alone, most commercial plans say no to both drugs. If you truly have type 2 diabetes, make sure it is in your chart. The diagnosis must be real, never added just to get coverage.

Check your plan's drug list, called a formulary, before you pick a brand. The easier drug is often simply the one your plan already covers.

Mounjaro and Ozempic on Medicare

With type 2 diabetes, a Part D drug plan can cover either drug. In 2026, your yearly out-of-pocket drug costs on Part D are capped at $2,100.

For weight loss alone, federal law bars Part D from paying for either drug. Medicare's separate GLP-1 Bridge charges $50 a month for weight-loss drugs, from July 1, 2026 to Dec 31, 2027. It covers Wegovy, Foundayo and the Zepbound KwikPen, not Mounjaro or Ozempic. People with type 2 diabetes cannot use the Bridge.

Mounjaro vs Ozempic side effects: is one easier to tolerate?

Both drugs cause the same kinds of stomach side effects. Nausea, vomiting, diarrhea and constipation are the most common. They come from how the drugs work. Both slow down digestion.

In SURMOUNT-5, stomach side effects were the most common problem in both groups. Most were mild to moderate. They showed up mainly while the dose was going up.

No trial shows that one drug is clearly easier on the stomach. Some women do better on one than the other, and there is no way to predict which. Our Ozempic side effects guide covers the common ones in more detail.

What's the real difference between Ozempic and Mounjaro?

Semaglutide works on one hormone target, called the GLP-1 receptor. It slows digestion and quiets hunger signals in the brain.

Tirzepatide works on that target plus a second one, called GIP. This dual action is the leading explanation for its bigger weight loss. Researchers are still sorting out how much comes from GIP and how much from the doses used.

For the deeper science, see semaglutide vs. tirzepatide. This page sticks to the two diabetes brands and what they cost you.

Each drug is sold under two brand names. Semaglutide is Ozempic for diabetes and Wegovy for weight loss. Since May 2026, Ozempic also comes as a daily pill, the drug once sold as Rybelsus. Tirzepatide is Mounjaro for diabetes and Zepbound for weight loss.

Mounjaro or Ozempic: which is right for you?

• You have type 2 diabetes and your plan covers one of them: pick the covered drug. With its savings card, it can cost as little as $25 a month.
• You want the strongest average result: Mounjaro has the better head-to-head evidence. Self-pay costs about $500 a month at every dose.
• You pay cash and price comes first: Ozempic usually costs less over a year. The Ozempic pill starts at about $150 a month.
• Weight loss is your real goal, not diabetes: ask about Zepbound or Wegovy. Their insurance and savings rules are built for weight loss.
• You're on Medicare and don't have diabetes: the GLP-1 Bridge covers Wegovy, Foundayo or the Zepbound KwikPen for $50 a month if you qualify.
• Nausea was a problem on a GLP-1 before: neither drug has a proven edge. Both start low and raise the dose slowly to limit stomach upset.

Can you switch from Ozempic to Mounjaro, or the reverse?

Yes. Clinicians make this switch often, after a plateau or side effects that are hard to live with.

There is no official dose conversion between the two drugs. Most prescribers restart the new drug at its lowest dose. They time the first shot around your weekly schedule so the two drugs do not overlap. The plan depends on how you did on the first drug.

What a switch does to your bill and your savings card is covered in Ozempic vs tirzepatide cost.

Is compounded tirzepatide or compounded semaglutide safe and legal?

Both can still be legal, but under tighter rules than before. Both drugs were compounded widely during FDA shortages. The tirzepatide shortage ended in December 2024. The semaglutide shortage ended in February 2025.

The FDA's grace period for compounders ended in the first half of 2025. What remains is a narrower path. A pharmacy can make the drug for one named patient with a clinical reason the approved version won't work. The FDA says cost alone is not such a reason.

One rule change is still pending. On April 30, 2026, the FDA proposed not to add either drug to its 503B bulks list. That list says which ingredients large outsourcing pharmacies may use. Comments closed on July 30, 2026, and no final decision had been posted as of October 2026.

Both makers have also sued telehealth compounders. Most of these suits are about marketing and business practices, not claims of fake medicine. Eli Lilly sued several in 2025. A judge dismissed its suit against Willow in February 2026, and Lilly has appealed. Others are still open. Novo Nordisk dropped its patent suit against Hims & Hers in March 2026, as part of a deal between the two companies.

What matters most is the pharmacy and the provider behind the drug. Look for a PCAB-accredited pharmacy, which means it passed an outside quality review. Ask the provider to name the pharmacy. Our compounded GLP-1 guide compares the sellers.

Mounjaro vs Ozempic for perimenopause and menopause weight gain

Weight often shifts toward the belly in perimenopause. Falling estrogen plays a part. It also makes the body handle blood sugar less well.

Both drugs reduce appetite and help the body handle blood sugar. No trial has compared Mounjaro and Ozempic in women in perimenopause or menopause. So there is no menopause-specific winner.

Without diabetes, the real choice is usually not between these two diabetes brands. It is between Zepbound, Wegovy and a compounded option.